NSE: VIJAYA | BSE: 543350

Expensive Performer

Download real time

1027.50 25.50 (2.54%)

38.85% Gain from 52W Low

47,082 NSE+BSE Volume

NSE 09 Jul, 2025 10:09 AM (IST)

10,551.1

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Vijaya Diagnostic Centre Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for VIJAYA, BSE:543350 Vijaya Diagnostic Centre Ltd.

Search Inside the pdf :

Vijaya Diagnostic Centre Ltd.

13 May 2025

1027.50

2.54%

On track execution; growth trajectory looks promising

Buy: Vijaya Diagnostic Centre Ltd.

Emkay

Vijaya’s Q4FY25 results were a slight miss on our estimates (2%/3% on sales/EBITDA) due to industry-level headwinds (extended festivities in South India), capacity constraints in Pune centers, and gross margin contraction.

Vijaya Diagnostic Centre Ltd. has gained 31.31% in the last 1 Year

Vijaya Diagnostic Centre Ltd.

07 Apr 2025

1027.50

2.54%

VIJAYA DIAGNOSTIC CEN LTD

Buy: Vijaya Diagnostic Centre Ltd.

FundsIndia

Vijaya Diagnostic Centre Ltd. is trading above all available SMAs

Vijaya Diagnostic Centre Ltd.

07 Aug 2024

1027.50

2.54%

PH relieves pain in margin of base business

Hold: Vijaya Diagnostic Centre Ltd.

Recommendation Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q1FY25 performance was ahead of our expectations. Base business grew at 19.6%driven by 16.6% YoY rise in patient footfall and 19.8% YoY jump in number of tests while EBITDA grew 17% YoY.

Number of FII/FPI investors increased from 155 to 181 in Mar 2025 qtr.

Vijaya Diagnostic Centre Ltd.

08 Nov 2023, 12:00AM

1027.50

2.54%

Striving for profitable growth; pricey valuation

Sell: Vijaya Diagnostic Centre Ltd.

Recommendation

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q2FY24 result was a beat vs our estimates driven by 18.3% YoY growth in non-covid business. Test volume growth remained healthy at 18.7% YoY. In Q2, it commercialised a new hub in Kolkata; the company is witnessing good traction and expects the hub to breakeven in next three quarters.

Number of FII/FPI investors increased from 155 to 181 in Mar 2025 qtr.

Vijaya Diagnostic Centre Ltd.

11 Aug 2023

1027.50

2.54%

Growth trajectory unhurt

Accumulate: Vijaya Diagnostic Centre Ltd.

Recommendation Target

ICICI Securities Limited

Vijaya’s Q1FY24 performance beat our estimates driven by 19.2% YoY growth in non covid business. Test volume growth remained healthy at 17.5% YoY, aided by improvement in footfalls in the company’s mature and newer centres. Centres at Panjagutta and Rajamundhry have started gaining traction while Tirupati hub is expected to scale up in the coming quarters.

Number of FII/FPI investors increased from 155 to 181 in Mar 2025 qtr.

Vijaya Diagnostic Centre Ltd.

31 May 2023

1027.50

2.54%

Non-covid patient footfall sturdy

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q4FY23 performance was driven by a steady 22.4% YoY growth in non-covid business, while covid business’ contribution fell to 1% (15% in Q4FY22). Overheads of new centres impacted EBITDA margin to a small extent though, at 40.6% in Q4, it continues to be better than that of most of listed peers.

Vijaya Diagnostic Centre Ltd. has gained 31.31% in the last 1 Year

Vijaya Diagnostic Centre Ltd.

16 Feb 2023

1027.50

2.54%

Steady performance, healthy outlook

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q3FY23 performance was broadly in line with our estimates. Revenues grew 2.1% YoY (-6.3% QoQ) to Rs1.1bn (I-Sec: Rs1.1bn). Covid revenues were negligible during the quarter. EBITDA margin declined 120bps QoQ to 39.1% (I-Sec: 38%) due to negative operating leverage.

Vijaya Diagnostic Ce.. has an average target of 1010.67 from 3 brokers.

Vijaya Diagnostic Centre Ltd.

14 Nov 2022

1027.50

2.54%

Growth momentum to continue

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q2FY23 performance was broadly in line with our estimates. Revenue grew 7.1% YoY and 15.7% QoQ to Rs1.2bn (I-Sec: Rs1.2bn).

Number of FII/FPI investors increased from 155 to 181 in Mar 2025 qtr.

Vijaya Diagnostic Centre Ltd.

11 Aug 2022

1027.50

2.54%

Healthy recovery in non-covid business

Buy: Vijaya Diagnostic Centre Ltd.

Target

ICICI Securities Limited

Vijaya Diagnostic Centre’s (Vijaya) Q1FY23 performance was broadly in line with our estimates with revenue declining 14.9% YoY to Rs1.0bn (I-Sec: Rs1.0bn) on a high covid base.

Vijaya Diagnostic Centre Ltd. has gained 31.31% in the last 1 Year

Vijaya Diagnostic Centre Ltd.

05 Jan 2022

1027.50

2.54%

B2C-focused dominant Southern player

Buy: Vijaya Diagnostic Centre Ltd.

ICICI Securities Limited

Vijaya Diagnostic (Vijaya) is one of the largest integrated diagnostic chains in southern India and is primarily based in Andhra Pradesh and Telangana. Other factors that differentiate Vijaya from other diagnostic chains are: 1) ~92% of business is its B2C (provides stickiness) and 2) it offers a comprehensive basket of diagnostic services in both pathology and radiology

Number of FII/FPI investors increased from 155 to 181 in Mar 2025 qtr.

VOTE: Is Vijaya Diagnostic Centre Ltd. worth buying?

40 Votes:

Buy 77.5%

Sell 15.0%

Hold 7.5%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf